BRD-810 shows optimized in vivo clearance and potent efficacy in xenograft models

Aug. 30, 2024

Trueline Therapeutics Inc. and Broad Institute Inc. have reported preclinical data for the novel myeloid cell leukemia 1 (MCL1) inhibitor, BRD-810, being developed for the treatment of cancer.

BioWorld Science Cancer

Today's news in brief

BioWorld

BioWorld briefs for Dec. 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 9, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...